Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glycogen Storage Disease Type II | 17 | 2023 | 23 | 7.670 |
Why?
|
| Respiratory Insufficiency | 10 | 2025 | 148 | 4.010 |
Why?
|
| Muscular Dystrophy, Duchenne | 4 | 2025 | 42 | 3.200 |
Why?
|
| Disease Models, Animal | 17 | 2025 | 2058 | 2.900 |
Why?
|
| Hypoglossal Nerve | 5 | 2024 | 6 | 2.750 |
Why?
|
| Spinocerebellar Ataxias | 3 | 2024 | 13 | 2.500 |
Why?
|
| alpha-Glucosidases | 8 | 2023 | 16 | 2.490 |
Why?
|
| Phrenic Nerve | 6 | 2024 | 8 | 2.190 |
Why?
|
| Genetic Therapy | 11 | 2022 | 706 | 1.850 |
Why?
|
| Diaphragm | 6 | 2025 | 23 | 1.660 |
Why?
|
| Motor Neurons | 6 | 2023 | 206 | 1.660 |
Why?
|
| Muscle, Skeletal | 8 | 2023 | 672 | 1.610 |
Why?
|
| Neuromuscular Diseases | 3 | 2023 | 23 | 1.590 |
Why?
|
| Dependovirus | 12 | 2022 | 655 | 1.500 |
Why?
|
| Lung Diseases | 3 | 2017 | 163 | 1.440 |
Why?
|
| Respiration | 4 | 2023 | 87 | 1.400 |
Why?
|
| Mice, Inbred mdx | 3 | 2025 | 18 | 1.390 |
Why?
|
| Dystrophin | 4 | 2025 | 35 | 1.350 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2020 | 474 | 1.320 |
Why?
|
| Mice | 25 | 2025 | 10237 | 1.150 |
Why?
|
| Genetic Vectors | 9 | 2022 | 797 | 1.120 |
Why?
|
| Mice, Transgenic | 5 | 2024 | 1219 | 1.080 |
Why?
|
| Glycogen | 8 | 2023 | 46 | 1.060 |
Why?
|
| Animals | 32 | 2025 | 19559 | 1.060 |
Why?
|
| Utrophin | 1 | 2025 | 5 | 0.990 |
Why?
|
| Lung Abscess | 1 | 2024 | 7 | 0.950 |
Why?
|
| Gene Transfer Techniques | 3 | 2018 | 304 | 0.940 |
Why?
|
| Enzyme Replacement Therapy | 4 | 2021 | 15 | 0.940 |
Why?
|
| Bronchoscopy | 1 | 2024 | 64 | 0.920 |
Why?
|
| Foreign Bodies | 1 | 2024 | 43 | 0.910 |
Why?
|
| Neurology | 1 | 2022 | 34 | 0.810 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 42 | 0.810 |
Why?
|
| Muscle, Smooth | 3 | 2021 | 139 | 0.780 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 720 | 0.760 |
Why?
|
| Retinal Degeneration | 1 | 2021 | 30 | 0.740 |
Why?
|
| Nerve Degeneration | 2 | 2023 | 68 | 0.740 |
Why?
|
| Mice, Knockout | 9 | 2025 | 1987 | 0.740 |
Why?
|
| Superoxide Dismutase | 3 | 2017 | 213 | 0.730 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 20 | 0.700 |
Why?
|
| Membrane Transport Proteins | 1 | 2020 | 119 | 0.680 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2017 | 53 | 0.670 |
Why?
|
| Axons | 1 | 2020 | 120 | 0.670 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2019 | 10 | 0.660 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2019 | 13 | 0.660 |
Why?
|
| Macroglossia | 1 | 2019 | 1 | 0.650 |
Why?
|
| Humans | 36 | 2024 | 59186 | 0.650 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 22 | 0.650 |
Why?
|
| Muscular Diseases | 1 | 2019 | 45 | 0.640 |
Why?
|
| Motor Neuron Disease | 1 | 2019 | 29 | 0.640 |
Why?
|
| Phenotype | 3 | 2023 | 1154 | 0.600 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 374 | 0.600 |
Why?
|
| Lung | 3 | 2023 | 822 | 0.590 |
Why?
|
| Neuromuscular Junction | 4 | 2024 | 82 | 0.580 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 28 | 0.580 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 46 | 0.560 |
Why?
|
| Down Syndrome | 1 | 2017 | 50 | 0.540 |
Why?
|
| Respiratory System Agents | 1 | 2015 | 6 | 0.510 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 63 | 0.510 |
Why?
|
| Isoxazoles | 1 | 2015 | 14 | 0.510 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 43 | 0.510 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 57 | 0.480 |
Why?
|
| Hypoxia | 1 | 2015 | 107 | 0.480 |
Why?
|
| Child, Preschool | 5 | 2024 | 1835 | 0.440 |
Why?
|
| Male | 13 | 2025 | 27445 | 0.440 |
Why?
|
| Ataxin-7 | 2 | 2024 | 2 | 0.430 |
Why?
|
| Child | 9 | 2023 | 4296 | 0.410 |
Why?
|
| Gene Targeting | 1 | 2012 | 82 | 0.390 |
Why?
|
| Inhalation Spacers | 1 | 2011 | 1 | 0.390 |
Why?
|
| Referral and Consultation | 1 | 2015 | 408 | 0.390 |
Why?
|
| Androstadienes | 1 | 2011 | 30 | 0.380 |
Why?
|
| Respiratory Function Tests | 3 | 2020 | 165 | 0.380 |
Why?
|
| Parents | 1 | 2015 | 378 | 0.370 |
Why?
|
| Bronchitis | 1 | 2011 | 25 | 0.370 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2011 | 30 | 0.370 |
Why?
|
| Medulla Oblongata | 2 | 2024 | 9 | 0.370 |
Why?
|
| Fontan Procedure | 1 | 2011 | 19 | 0.370 |
Why?
|
| Spinal Cord | 3 | 2024 | 195 | 0.360 |
Why?
|
| Smoking | 1 | 2015 | 830 | 0.350 |
Why?
|
| Smoking Cessation | 1 | 2015 | 531 | 0.340 |
Why?
|
| Heart Transplantation | 1 | 2011 | 158 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3182 | 0.300 |
Why?
|
| Tongue | 2 | 2024 | 17 | 0.280 |
Why?
|
| Gene Expression | 2 | 2019 | 806 | 0.250 |
Why?
|
| Hypoventilation | 1 | 2025 | 5 | 0.250 |
Why?
|
| Hemiplegia | 2 | 2023 | 6 | 0.240 |
Why?
|
| Superoxide Dismutase-1 | 3 | 2020 | 134 | 0.230 |
Why?
|
| Receptors, Cholinergic | 1 | 2024 | 22 | 0.230 |
Why?
|
| Female | 9 | 2024 | 30766 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 48 | 0.230 |
Why?
|
| Astrocytes | 1 | 2024 | 114 | 0.220 |
Why?
|
| Drainage | 1 | 2024 | 144 | 0.220 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2023 | 6 | 0.220 |
Why?
|
| Bulbo-Spinal Atrophy, X-Linked | 1 | 2023 | 2 | 0.220 |
Why?
|
| Respiratory Muscles | 2 | 2013 | 8 | 0.220 |
Why?
|
| Apnea | 1 | 2023 | 31 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 86 | 0.220 |
Why?
|
| Transduction, Genetic | 3 | 2022 | 226 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5134 | 0.210 |
Why?
|
| Dysarthria | 1 | 2022 | 8 | 0.210 |
Why?
|
| Pulmonary Medicine | 1 | 2023 | 25 | 0.210 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2023 | 21 | 0.210 |
Why?
|
| Epilepsy | 1 | 2023 | 106 | 0.210 |
Why?
|
| Asthma | 2 | 2017 | 417 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2020 | 617 | 0.200 |
Why?
|
| Infant | 2 | 2017 | 1526 | 0.190 |
Why?
|
| Methacholine Chloride | 2 | 2021 | 27 | 0.190 |
Why?
|
| Muscle Relaxation | 1 | 2021 | 25 | 0.180 |
Why?
|
| Adolescent | 3 | 2020 | 5912 | 0.180 |
Why?
|
| Taste | 1 | 2021 | 32 | 0.180 |
Why?
|
| Peptides | 1 | 2024 | 546 | 0.180 |
Why?
|
| Deglutition | 1 | 2020 | 19 | 0.180 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 127 | 0.170 |
Why?
|
| Muscle Contraction | 2 | 2021 | 198 | 0.170 |
Why?
|
| Gene Deletion | 1 | 2021 | 297 | 0.170 |
Why?
|
| Carnitine | 1 | 2019 | 21 | 0.160 |
Why?
|
| Cell Line | 1 | 2023 | 2011 | 0.160 |
Why?
|
| Mice, 129 Strain | 2 | 2016 | 40 | 0.160 |
Why?
|
| Survivors | 1 | 2020 | 148 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 422 | 0.160 |
Why?
|
| Gene Editing | 1 | 2022 | 285 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1310 | 0.150 |
Why?
|
| Young Adult | 2 | 2020 | 4314 | 0.150 |
Why?
|
| Liver | 2 | 2019 | 782 | 0.150 |
Why?
|
| Enzyme Activation | 1 | 2018 | 351 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 200 | 0.140 |
Why?
|
| Potassium Chloride | 1 | 2017 | 15 | 0.140 |
Why?
|
| Pulmonary Emphysema | 1 | 2018 | 86 | 0.140 |
Why?
|
| Albuterol | 1 | 2017 | 20 | 0.140 |
Why?
|
| Extracellular Space | 1 | 2017 | 30 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 86 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 1454 | 0.140 |
Why?
|
| Bronchi | 1 | 2017 | 76 | 0.140 |
Why?
|
| Trachea | 1 | 2017 | 92 | 0.140 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 304 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 846 | 0.130 |
Why?
|
| Synaptic Potentials | 1 | 2015 | 7 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2017 | 174 | 0.130 |
Why?
|
| Calcium Signaling | 1 | 2017 | 152 | 0.130 |
Why?
|
| Brain Stem | 1 | 2015 | 30 | 0.130 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2016 | 77 | 0.130 |
Why?
|
| Florida | 1 | 2015 | 40 | 0.120 |
Why?
|
| Hotlines | 1 | 2015 | 22 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1108 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 96 | 0.120 |
Why?
|
| Intention | 1 | 2015 | 66 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 110 | 0.120 |
Why?
|
| Prognosis | 1 | 2018 | 1564 | 0.110 |
Why?
|
| Myofibrils | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 151 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 69 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 131 | 0.110 |
Why?
|
| Caregivers | 1 | 2015 | 216 | 0.100 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 2023 | 22 | 0.100 |
Why?
|
| Motor Activity | 1 | 2015 | 342 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 731 | 0.100 |
Why?
|
| Metered Dose Inhalers | 1 | 2011 | 5 | 0.100 |
Why?
|
| Fluticasone | 1 | 2011 | 13 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 191 | 0.100 |
Why?
|
| Sputum | 1 | 2011 | 36 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 669 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 119 | 0.090 |
Why?
|
| Azithromycin | 1 | 2011 | 26 | 0.090 |
Why?
|
| Heart | 1 | 2013 | 274 | 0.090 |
Why?
|
| Adult | 2 | 2020 | 15707 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 655 | 0.090 |
Why?
|
| Risk Factors | 2 | 2017 | 4995 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 397 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 95 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 284 | 0.090 |
Why?
|
| Cough | 1 | 2011 | 182 | 0.080 |
Why?
|
| Mutation | 3 | 2023 | 2422 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1446 | 0.070 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2024 | 2 | 0.060 |
Why?
|
| Receptors, Androgen | 1 | 2023 | 29 | 0.050 |
Why?
|
| Protein Domains | 1 | 2024 | 138 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 129 | 0.050 |
Why?
|
| Seizures | 1 | 2023 | 117 | 0.050 |
Why?
|
| Macaca | 1 | 2022 | 28 | 0.050 |
Why?
|
| Swine | 1 | 2022 | 338 | 0.050 |
Why?
|
| Stem Cells | 1 | 2023 | 254 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2023 | 374 | 0.050 |
Why?
|
| Respiratory System | 1 | 2021 | 41 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 93 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 421 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 549 | 0.040 |
Why?
|
| Middle Aged | 1 | 2015 | 16208 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 1308 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 696 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2016 | 17 | 0.030 |
Why?
|
| Lateral Ventricles | 1 | 2016 | 8 | 0.030 |
Why?
|
| Neuroimmunomodulation | 1 | 2016 | 9 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 35 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2016 | 33 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 52 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 84 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 230 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 105 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 1203 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 116 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 100 | 0.030 |
Why?
|
| Pediatrics | 1 | 2017 | 266 | 0.030 |
Why?
|
| Tibia | 1 | 2014 | 70 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 274 | 0.030 |
Why?
|
| Pleura | 1 | 2013 | 11 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 377 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 198 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 630 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1038 | 0.020 |
Why?
|
| Myocardium | 1 | 2013 | 262 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1034 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2434 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 5959 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 436 | 0.020 |
Why?
|
| Aged | 1 | 2023 | 13271 | 0.020 |
Why?
|